Pier Giorgio Cojutti

Employment

• University of Bologna Senior assistant professor
  2022 - Present
• Azienda Ospedaliero-Universitaria di Bologna IRCCS Medical doctor
  2021 - Present

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (74)

• Could a Reduced Dose of 8 g of Continuous Infusion Fosfomycin Be Considered as Effective as and Safer than a Standard 16 g Dose When Combined with High-Dose Daptomycin in the Treatment of Staphylococcal osteoarticular Infections?
  Antibiotics 2025 DOI: 10.3390/antibiotics14020139
  +Save
• Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients
  Critical Care 2022 DOI: 10.1186/s13054-022-04050-9
  +Save
• Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency
  Clinical pharmacokinetics 2022 DOI: 10.1007/s40262-021-01079-x
  +Save
• Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime–Avibactam-Based Regimens: A Report of Two Cases
  Microorganisms 2022 DOI: 10.3390/microorganisms10010154
  +Save
• Reply to Baklouti et al., "Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?"
  Antimicrobial Agents and Chemotherapy 2022 DOI: 10.1128/AAC.01908-21
  +Save
• Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like Klebsiella pneumoniae Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring
  Infectious Disease Reports 2022 DOI: 10.3390/idr14010010
  +Save
• A Proof of Concept of the Role of TDM-Based Clinical Pharmacological Advices in Optimizing Antimicrobial Therapy on Real-Time in Different Paediatric Settings
  Frontiers in Pharmacology 2021 DOI: 10.3389/fphar.2021.755075
  +Save
• A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associ…
  Journal of Global Antimicrobial Resistance 2021 DOI: 10.1016/j.jgar.2021.10.014
  +Save
• Assessment of a pk/pd target of continuous infusion beta-lactams useful for preventing microbiological failure and/or resistance development in critically ill patients affected by documented gram-negative infections
  Antibiotics 2021 DOI: 10.3390/antibiotics10111311
  +Save
• Authors’ Reply to Cattaneo et al.: “Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6”
  Clinical Pharmacokinetics 2021 DOI: 10.1007/s40262-021-00996-1
  +Save
• Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization
  Frontiers in Pharmacology 2021 DOI: 10.3389/fphar.2021.781892
  +Save
• Population pharmacokinetics and monte carlo simulation for dosage optimization of fosfomycin in the treatment of osteoarticular infections in patients without renal dysfunction
  Antimicrobial Agents and Chemotherapy 2021 DOI: 10.1128/AAC.02038-20
  +Save
• Population pharmacokinetics and pharmacodynamic target attainment of isavuconazole against aspergillus fumigatus and aspergillus flavus in adult patients with invasive fungal diseases: Should therapeutic drug monitoring for isavuconazole be considered as…
  Pharmaceutics 2021 DOI: 10.3390/pharmaceutics13122099
  +Save
• Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa
  International Journal of Antimicrobial Agents 2021 DOI: 10.1016/j.ijantimicag.2021.106408
  +Save
• Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections
  Antimicrobial Agents and Chemotherapy 2021 DOI: 10.1128/AAC.02260-20
  +Save
• Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept
  International Journal of Antimicrobial Agents 2021 DOI: 10.1016/j.ijantimicag.2021.106445
  +Save
• Population Pharmacokinetics of Continuous-Infusion Meropenem in Febrile Neutropenic Patients with Hematologic Malignancies: Dosing Strategies for Optimizing Empirical Treatment against Enterobacterales and P. aeruginosa
  Pharmaceutics 2020 DOI: 10.3390/pharmaceutics12090785
  +Save
• Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6
  Clinical Pharmacokinetics 2020 DOI: 10.1007/s40262-020-00933-8
  +Save
• Covid-19 and the role of smoking: The protocol of the multicentric prospective study COSMO-IT (covid19 and smoking in italy)
  Acta Biomedica 2020 DOI: 10.23750/abm.v91i3.10373
  +Save
• Real-Time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: Results from a prospective, monocentric, interventional study
  Journal of Antimicrobial Chemotherapy 2020 DOI: 10.1093/jac/dkaa267
  +Save